Alternatives to albumin: Starch replacement for plasma exchange

Nanoparticles Based on Modified Polysaccharides

“…Hydrophilic amylopectin was modified by grafting hydrophobic poly (lactic acid) chains (PLA) for the fabrication of polymeric micelles for drug delivery. When these spherical nano-aggregates were used as the drug carrier, it was found that they had a good loading capacity and in vitro release properties for hydrophobic indomethacin drug (Brecher et al, 1997;Dufresne et al, 2006).…”

Reducing the economic burden in management of Guillain–Barre syndrome using modified plasmapheresis

“…HES is well-tolerated and cost-effective as full or partial volume replacement with plasma exchange. [11] Colloid starch should be avoided in patients with renal failure, congestive heart failure, pulmonary edema, hyperviscosity, corn or starch allergy, coagulopathies, and liver failure. [10] No side effect due to use of FFP and 6% HES was observed in this study.…”

Biobetters

“…Although HES was initially considered to be non-toxic and safe in its primary use as a plasma volume expander (Brecher et al 1997 ), this assumption has been challenged as clinical trials revealed an increased risk of death and renal impairment in septic patients treated with HES (Ghijselings and Rex 2014 ;Perel and Roberts 2007 ;Zarychanski et al 2013 ). As a consequence, the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA recommended suspending marketing authorizations for infusion solutions containing hydroxyethyl starch (EMA 2013a ) and the FDA also communicated a serious warning with respect to the use of HES as plasma expander (FDA 2013 ).…”